Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

Name: Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
Published: 2025
License: Public Domain

AbbVie · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

acute-myeloid-leukemia

acute myeloid leukemia, aml, venetoclax, venclexta, azacitidine, treatment naïve aml, untreated aml, interventional, phase4

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

Related documents